ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation

blonca9
3 days ago
1 min read

He describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein degradation field in general.

Recent Posts

See All

Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data

ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight